Suppr超能文献

急性肾损伤对接受经动脉化疗栓塞治疗的肝细胞癌患者的影响。

Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

机构信息

Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.

出版信息

PLoS One. 2020 Dec 14;15(12):e0243780. doi: 10.1371/journal.pone.0243780. eCollection 2020.

Abstract

The purpose of this study was to investigate the effect of acute kidney injury (AKI) on the prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). A total of 347 HCC patients with Child-Pugh class A and pre-TACE serum creatinine (SCr) ≤1.5 mg/dL undergoing TACE as an initial therapy 2000-2014 were analyzed. Overall survival with related risk factors including AKI was investigated. We assessed AKI based on the International Club of Ascites (ICA)-AKI criteria. The mean age was 60.9 years. Of 347 patients, death was observed in 109 patients (31.4%). The mean SCr levels at pre-TACE, one day, two months, and four months after TACE were 0.9, 0.9, 0.9, and 1.1 mg/dL, respectively. The AKI within four months after TACE developed in 37 patients (11%). The AKI stages were non-AKI in 310 (89%), stage 1 in 10 (3%), stage 2 in 10 (3%), and stage 3 in 17 patients (5%). Multivariable analysis showed that the risk factors for overall survival were serum albumin ≤3.5 g/dL (hazard ratio [HR] 1.58, p = 0.027), BCLC stage B (HR 2.07, p = 0.008), BCLC stage C (HR 3.96, p<0.001), bilobar tumor location (HR 1.66, p = 0.022), AKI stage 1 (HR 6.09, p<0.001), AKI stage 2 (HR 8.51, p<0.001), and AKI stage 3 (HR 17.64, p<0.001). AKI is a crucial prognostic factor for overall survival in HCC patients undergoing TACE. The assessment of AKI based on the ICA-AKI criteria can facilitate evaluation of the prognosis of HCC patients undergoing TACE.

摘要

本研究旨在探讨急性肾损伤(AKI)对接受经导管肝动脉化疗栓塞术(TACE)治疗的肝细胞癌(HCC)患者预后的影响。分析了 2000 年至 2014 年间共 347 例 Child-Pugh 分级为 A 级且 TACE 前血清肌酐(SCr)≤1.5mg/dL 的 HCC 患者,这些患者均接受 TACE 作为初始治疗。对包括 AKI 在内的相关危险因素与总生存率进行了研究。我们根据国际腹水俱乐部(ICA)-AKI 标准评估 AKI。患者平均年龄为 60.9 岁。347 例患者中,有 109 例(31.4%)死亡。TACE 前、第 1 天、第 2 个月和第 4 个月的平均 SCr 水平分别为 0.9、0.9、0.9 和 1.1mg/dL。TACE 后 4 个月内有 37 例(11%)发生 AKI。AKI 分期为非 AKI 310 例(89%),1 期 10 例(3%),2 期 10 例(3%),3 期 17 例(5%)。多变量分析显示,总生存率的危险因素包括血清白蛋白≤3.5g/dL(风险比[HR]1.58,p=0.027)、BCLC 分期 B(HR 2.07,p=0.008)、BCLC 分期 C(HR 3.96,p<0.001)、双叶肿瘤位置(HR 1.66,p=0.022)、AKI 分期 1(HR 6.09,p<0.001)、AKI 分期 2(HR 8.51,p<0.001)和 AKI 分期 3(HR 17.64,p<0.001)。AKI 是 TACE 治疗 HCC 患者总生存率的一个关键预后因素。基于 ICA-AKI 标准评估 AKI 有助于评估 TACE 治疗 HCC 患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/570f/7735598/e8a1949c13ba/pone.0243780.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验